Liyi Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Liyi Xu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Arijit Ghosh
Department of Electrical Communication Engineering, Indian Institute of Science, Bangalore, India
3 shared publications - David H. Gracias
Department of Chemical and Biomolecular Engineering Johns Hopkins University Baltimore MD 21218 USA
3 shared publications - Florin M. Selaru
Division of Gastroenterology and Hepatology, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA
3 shared publications - Gayatri Pahapale
Johns Hopkins University
3 shared publications - Ling Li
Division of Gastroenterology and Hepatology, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA
3 shared publications - Wangqu Liu
Department of Chemical and Biomolecular Engineering Johns Hopkins University Baltimore MD 21218 USA
3 shared publications
Latest Publications
- 6 October 2022
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 16 (10) , 16211-16220
Autonomous Untethered Microinjectors for Gastrointestinal Delivery of Insulin
The delivery of macromolecular drugs via the gastrointestinal (GI) tract is challenging as these drugs display low stability as well as poor absorption across the intestinal epithelium. While permeation-enhancing drug delivery methods can increase the bioavailability of low molecular weight drugs, the effective delivery of high molecular weight drugs across the tight epithelial cell junctions remains a formidable challenge. Here, we describe autonomous microinjectors that are deployed in the GI tract, then efficiently penetrate the GI mucosa to deliver a macromolecular drug, insulin, to the systemic circulation. We performed in vitro studies to characterize insulin release and assess the penetration capability of microinjectors and we measured the in vivo release of insulin in live rats. We found that the microinjectors administered within the luminal GI tract could deliver insulin transmucosally to the systemic circulation at levels similar to those with intravenously administered insulin. Due to their small size, tunability in sizing and dosing, wafer-scale fabrication, and parallel, autonomous operation, we anticipate that these microinjectors will significantly advance drug delivery across the GI tract mucosa to the systemic circulation in a safe manner.
- 6 October 2022
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 16 (10) , 16211-16220
Autonomous Untethered Microinjectors for Gastrointestinal Delivery of Insulin
The delivery of macromolecular drugs via the gastrointestinal (GI) tract is challenging as these drugs display low stability as well as poor absorption across the intestinal epithelium. While permeation-enhancing drug delivery methods can increase the bioavailability of low molecular weight drugs, the effective delivery of high molecular weight drugs across the tight epithelial cell junctions remains a formidable challenge. Here, we describe autonomous microinjectors that are deployed in the GI tract, then efficiently penetrate the GI mucosa to deliver a macromolecular drug, insulin, to the systemic circulation. We performed in vitro studies to characterize insulin release and assess the penetration capability of microinjectors and we measured the in vivo release of insulin in live rats. We found that the microinjectors administered within the luminal GI tract could deliver insulin transmucosally to the systemic circulation at levels similar to those with intravenously administered insulin. Due to their small size, tunability in sizing and dosing, wafer-scale fabrication, and parallel, autonomous operation, we anticipate that these microinjectors will significantly advance drug delivery across the GI tract mucosa to the systemic circulation in a safe manner.
- Open Access
Autonomous untethered microinjectors for gastrointestinal delivery of insulin
The delivery of macromolecular drugs via the gastrointestinal (GI) tract is challenging. Macromolecular drugs display low stability and poor absorption across the intestinal epithelium. While permeation-enhancing drug delivery methods can increase the bioavailability of low molecular weight drugs, the effective delivery of high molecular weight drugs across the tight epithelial cell junctions remains a formidable challenge. Here, we describe autonomous microinjectors that can efficiently penetrate the GI mucosa and deliver insulin systemically. In addition, we performed in vitro studies to characterize insulin release and the penetration capacity of microinjectors and measure in vivo release of insulin in live rats. We found that the microinjectors administered within the luminal GI tract could deliver insulin trans-mucosally to the systemic circulation at similar levels to intravenously administered insulin. Due to their small size, tunability in sizing and dosing, wafer-scale fabrication, and parallel, autonomous operation, we anticipate that these novel microinjectors could significantly advance drug delivery across the GI tract mucosa to the systemic circulation.
Open AccessAutonomous untethered microinjectors for gastrointestinal delivery of insulin
The delivery of macromolecular drugs via the gastrointestinal (GI) tract is challenging. Macromolecular drugs display low stability and poor absorption across the intestinal epithelium. While permeation-enhancing drug delivery methods can increase the bioavailability of low molecular weight drugs, the effective delivery of high molecular weight drugs across the tight epithelial cell junctions remains a formidable challenge. Here, we describe autonomous microinjectors that can efficiently penetrate the GI mucosa and deliver insulin systemically. In addition, we performed in vitro studies to characterize insulin release and the penetration capacity of microinjectors and measure in vivo release of insulin in live rats. We found that the microinjectors administered within the luminal GI tract could deliver insulin trans-mucosally to the systemic circulation at similar levels to intravenously administered insulin. Due to their small size, tunability in sizing and dosing, wafer-scale fabrication, and parallel, autonomous operation, we anticipate that these novel microinjectors could significantly advance drug delivery across the GI tract mucosa to the systemic circulation.
- Open Access
- 30 October 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (44) , eabb4133
Gastrointestinal-resident, shape-changing microdevices extend drug release in vivo
Hookworm inspired, autonomous latching on the gastrointestinal mucosa extends the in vivo retention of a drug delivery device.
- 30 October 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (44) , eabb4133
Open AccessGastrointestinal-resident, shape-changing microdevices extend drug release in vivo
Hookworm inspired, autonomous latching on the gastrointestinal mucosa extends the in vivo retention of a drug delivery device.